血清素能抗抑郁药与连续流左心室辅助装置患者出血住院风险
该单中心回顾性分析纳入2016—2019年100例连续流左心室辅助装置(CF-LVAD)患者,比较植入后使用血清素能抗抑郁药(SA)者与未使用者。SA组出血住院比例更高(46% vs 15%,p=0.004),每患者年出血住院率更高(0.61 vs 0.3,p=0.01),差异主要由非消化道部位出血驱动。
要点
- CF-LVAD植入后使用SA与出血住院风险升高相关(HR 2.3,95%CI 0.99-5.4)。
- SA组非消化道出血住院比例更高(28% vs 6%,p=0.02)。
- SA组每患者年出血住院率高于未用SA组(0.61 vs 0.3,p=0.01)。
核心结论
- CF-LVAD植入后接受SA治疗与需住院的出血并发症风险增加相关,尤其是非消化道出血。
研究设计与样本
- 单中心回顾性分析,纳入2016—2019年本院100例CF-LVAD患者,比较植入后使用SA者与未使用者。
主要发现
- 无SA史者5例与CF-LVAD植入后处方SA者31例因出血事件再入院(15% vs 46%,p=0.004)。
- 每患者年出血率在未用SA者中显著更低(0.3 vs 0.61,p=0.01)。
- 年龄校正多变量分析显示SA使用与出血住院相关(HR 2.3,95%CI 0.99-5.4)。
- 出血住院增加由非消化道部位驱动(6% vs 28%,p=0.02),HR 7.7(95%CI 0.96-62)。
临床怎么用
- 对CF-LVAD患者处方SA时应评估出血风险,尤其关注非消化道出血,并加强随访监测。
局限性
- 为单中心回顾性研究,样本量100例,部分关联估计的置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Continuous flow left ventricular assist devices (CF -LVAD) improve survival in patients with advanced heart failure, but confer risk of bleeding complications. Serotonergic antidepressants (SA) are commonly used in heart failure patients receiving LVADs, but their inhibitory effect on platelet function may contribute to bleeding risk. METHODS: We performed a retrospective analysis of LVAD patients at our institution from 2016 -2019 comparing patients treated with SA after LVAD to those without SA. Demographic and clinical variables related to bleeding were collected on discharge from index hospitalization for CF-LVAD implantation and on admission for any bleeding event. The primary endpoint was incidence of bleeding requiring hospitalization after discharge. Secondary endpoints included overall number of admissions for bleeding, time to first hospitalization for a bleeding event, and incidence rate of hospitalizations for bleeding per patient year. RESULTS: 100 patients met inclusion criteria for the study. A total of 5 patients without a history of SA use and 31 patients who were prescribed SA after CF -LVAD implant were readmitted for a bleeding event after initial implant hospitalization (15% vs 46%, p = 0.004). Bleeding rate per person year (0.3 vs 0.61, p = 0.01) were significantly less in patients without SA use. Age-adjusted multivariable analysis found SA use to be associated with a hospitalization for bleeding (HR 2.3, 95% CI 0.99 -5.4). The higher incidence of hospitalization for bleeding was driven by non-gastrointestinal anatomical sites (6% vs 28%, p = 0.02) with a HR 7.7 (95% CI 0.96 -62). CONCLUSIONS: SA treatment after CF-LVAD implantation was associated with an increased risk for bleeding complications requiring hospitalization, particularly non-gastrointestinal bleeding.
引用
- Behrend K, Lillyblad M, Skelton P, et al. Serotonergic antidepressants and hospitalization for bleeding in patients supported with a continuous flow left ventricular assist device. J Heart Lung Transplant. 2021. PMID: 34419371. doi:10.1016/j.healun.2021.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。